Asthma is a common chronic condition that causes substantial morbidity among children and much of it is attributable to medication non-adherence. The National Asthma Education and Prevention Program (NAEPP) and the American Academy of Asthma, Allergy, and Immunology have urged others to develop more effective adherence programs.Schools are a logical setting to deploy such interventions because they are where children congregate, spend much of their day, and are frequently monitored. Because many schools serve a high proportion of minority and low-income students, engaging them presents a unique opportunity to reach populations who experience the greatest burden of preventable morbidity.
Supervising inhaled corticosteroid (ICS) use in the school setting can increase medication adherence and reduce episodes of poor asthma control. Under certain conditions, it can also be cost-effective. However, recruiting children from school settings tends to enroll children with mild asthma and infrequent health care use. Therefore, initiating supervised treatment in these children tends to burden school personnel with unnecessary work and diminishes the program's cost-effectiveness. To address this inefficiency, the investigators propose to recruit children who are discharged from the Hospital Emergency Departments (EDs) following successful treatment of an asthma attack. Such children have much higher risk of a future asthma attack than their peers.
The Pediatric Emergency Care Applied Research Network (PECARN) com- prises10 hospital-affiliated EDs that serve 1 million acutely ill and injured children annually. Their primary research mission is to reduce childhood morbidity and mortality by establishing creative partnerships between emergency medical service providers and their surrounding communities. The networks size and geographic diversity make it uniquely situated to develop, implement, and evaluate the feasibility and effectiveness of ED-Initiated School-Based Asthma Medication Supervision (ED-SAMS).
Approximately one-third of children treated for an asthma attack within PECARN experience a second ED-managed attack within 6 months. While the NAEPP guidelines recommend that long-term ICS treatment should be initiated at ED discharge, <20% of children actually receive a prescription for controller therapy. Observational data indicate that patients who use ICS following discharge are almost half as likely as non-users to experience a repeat ED visit. Many have also argued that ED-initiated treatment could be cost-effective. However, simply providing patients with a prescription does not ensure that they will actually use it once discharged. To ensure better medication adherence, the investigators propose to dispense ICS at discharge and supervise its use in the school setting.

开始日期2019-08-01

申办/合作机构-

NCT02802111 / CompletedN/AIIT

Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison With Levalbuterol in Healthy Adult Volunteers

Albuterol is the most commonly used β agonist to treat reversible lower airway obstruction. Albuterol contains a racemic mixture of two enantiomers. Levalbuterol contains the single R form enantiomer. Levalbuterol is frequently prescribed to limit cardiovascular toxicity. The investigators sought to examine the changes in oxygen consumption (V'O2) and Heart Rate (HR) following administration of albuterol and

开始日期2015-06-01

申办/合作机构

Children's Hospital Los Angeles

NCT01833026 / CompletedN/AIIT

Comparative Effectiveness of COPD Assessment and Management Bundle Versus Usual Care in Patients Suspected of Having COPD

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory (lung) disease that makes it harder to breathe over time. To date, there is no cure for COPD, but it can be managed when diagnosed and proper medical care is provided.
The purpose of this study is to determine if diagnosis and guided therapy with the use of spirometry is related to better patient outcomes (the condition of a patient's health) compared to usual care which may or may not include the use of spirometry. Spirometry is a standardized test used in medical practice that measures how much air your lungs can hold and how forcefully you can breathe out.
For this study, the investigators will compare two groups: 1) intervention (treatment) group and 2) usual care group (control). The intervention group will have a spirometry test and the results will be provided to the primary care physician. The usual care group will not initially have a spirometry test. Both groups will be followed for outcomes.

开始日期2013-03-01

申办/合作机构

University of Illinois

[+1]

100 项与盐酸左沙丁胺醇相关的临床结果

登录后查看更多信息

100 项与盐酸左沙丁胺醇相关的转化医学

登录后查看更多信息

100 项与盐酸左沙丁胺醇相关的专利（医药）

登录后查看更多信息

项与盐酸左沙丁胺醇相关的文献（医药）

2008-04-01·The Journal of the American Osteopathic Association

Paradoxical response to levalbuterol.

Article

作者: Dennis E Amundson ; Sarah E Broski

Asthma is a common condition that can substantially affect patients' quality of life. Although several drugs, most commonly beta-adrenergic agonists, alleviate symptoms of asthma, they may cause paradoxical bronchospasm or paradoxical bronchoconstriction. Levalbuterol hydrochloride-a pure form of the (R)-stereoisomer in racemic albuterol-eliminates the adrenergic properties that can cause such adverse effects. However, we report a case of paradoxical bronchoconstriction in a 36-year-old man who was recently diagnosed as having new-onset asthma and was treated with levalbuterol.

2004-07-01·The Journal of the American Osteopathic Association

Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease.

Review

作者: Gilbert E. D'Alonzo

Effective asthma control requires long-term (anti-inflammatory) controller medications for patients with mild-persistent to severe-persistent disease, and quick-relief bronchodilator medication for all patients with asthma to control intermittent symptoms of cough, wheeze, and bronchoconstriction, as well as acute exacerbations. For patients with chronic obstructive pulmonary disease, quick-relief and long-acting bronchodilators are primarily used in the maintenance and treatment of associated symptoms, including shortness of breath. For many years, the most widely used bronchodilator has been racemic (R, S)-albuterol, a short-acting beta2-adrenergic agonist, commonly dispensed as an inhaled aerosol or solution. Until the introduction of levalbuterol inhalation solution (Xopenex) in 1999, all marketed forms of albuterol (including Ventolin and Proventil brands) were racemic mixtures composed of a 1:1 ratio of (R)- and (S)-stereoisomers. Administered as a proportionally equivalent nebulized dose, levalbuterol [(R)-albuterol] provides greater bronchodilation than racemic albuterol and, in the appropriate clinical setting, offers the possibility for improving clinical outcomes in patients with asthma and other obstructive airway diseases. Additionally, levalbuterol can be given at lower doses than racemic albuterol to provide comparable bronchodilation, with the potential for reduced beta-mediated adverse effects in adults and children. Only since the past decade has the technology to separate stereoisomers become available, and thus the biologic activities of the albuterol stereoisomers had not been established. Binding studies have demonstrated that (R)-albuterol binds to the beta2-adrenergic receptor with a high affinity, whereas (S)-albuterol binds with 100-fold less affinity than (R)-albuterol. Other evaluations have suggested that (R)-albuterol possesses the bronchodilatory, bronchoprotective, and ciliary-stimulatory properties of racemic albuterol, while (S)-albuterol does not contribute beneficially to the therapeutic effects of the racemate and was originally assumed to be inert. However, preclinical evaluations have shown that (S)-albuterol has effects that work in opposition to (R)-albuterol and may diminish the therapeutic effects of (R)-albuterol.

2004-06-01·The Annals of pharmacotherapy4区 · 医学

Compatibility of Budesonide Inhalation Suspension with Four Nebulizing Solutions

4区 · 医学

Article

作者: Cruz-Rivera, Mario ; McKenzie, Jane E

BACKGROUND::

Nebulizable medications often are mixed to simplify asthma medication regimens.

OBJECTIVE::

To establish the in vitro chemical compatibility and stability of budesonide inhalation suspension 0.25 mg/2 mL and 0.5 mg/2 mL mixed in Pari LC Plus jet nebulizer cups with 3 mL of levalbuterol hydrochloride 0.63 mg/3 mL and 1.25 mg/3 mL; 0.5 mL of albuterol sulfate 5 mg/mL; 2 mL of cromolyn sodium 20 mg/2 mL; or 2.5 mL of ipratropium bromide 0.2 mg/mL.

METHODS::

We developed and validated isocratic HPLC methods to permit separation of the admixture components from aliquots taken 0, 5, 15, and 30 minutes after mixing. Admixtures were prepared and analyzed at room temperature. Each assay was conducted 3 times using separate nebulizer cups. All components were quantified by external standards using HPLC-derived peak area. Appearance and pH of the admixtures were recorded.

RESULTS::

No additional peaks occurred in any HPLC chromatogram for any medication from any admixture. With the exception of ipratropium bromide at 93%, each admixture retained >97% of the initial concentration of each medication in the nebulizer cup. There was no significant change in pH or visual identification of a precipitate in any admixture of active drugs.

CONCLUSIONS::

These data support the chemical compatibility of budesonide inhalation suspension for up to 30 minutes with other commonly used nebulized medications for controlling pediatric asthma symptoms.

107

项与盐酸左沙丁胺醇相关的新闻（医药）

2024-06-24

·信狐药迅

仿制药申请12个品规、进口上市4个品规发通知件；临床申请品种均默示许可| 新获批（6.17-6.23）

每周药品注册获批数据，分门别类呈现，一目了然。(6.17-6.23）新药上市申请药品名称企业注册分类受理号TQ-B3139胶囊正大天晴药业集团南京顺欣制药有限公司1CXHS2200026国;CXHS2200026TQ-B3139胶囊正大天晴药业集团南京顺欣制药有限公司1CXHS2200025国;CXHS2200025TQ-B3139胶囊正大天晴药业集团南京顺欣制药有限公司1CXHS2200024国;CXHS2200024甲磺酸奥瑞替尼片南京圣和药业股份有限公司1CXHS2101058国;CXHS2101058 新药临床申请药品名称企业注册分类受理号HRS-9813片广东恒瑞医药有限公司1CXHL2400397HRS-9813片广东恒瑞医药有限公司1CXHL2400396PZH2113 胶囊漳州片仔癀药业股份有限公司1CXHL2400372PZH2113 胶囊漳州片仔癀药业股份有限公司1CXHL2400371WD-890片浙江文达医药科技有限公司1CXHL2400361WD-890片浙江文达医药科技有限公司1CXHL2400360WD-890片浙江文达医药科技有限公司1CXHL2400359WD-890片浙江文达医药科技有限公司1CXHL2400358ZX-8177片南京征祥医药有限公司1CXHL2400347ZX-8177片南京征祥医药有限公司1CXHL2400346西奥罗尼胶囊深圳微芯生物科技股份有限公司1CXHL2400342西奥罗尼胶囊深圳微芯生物科技股份有限公司1CXHL2400341RS-C1001片青岛睿森生物科技有限公司1CXHL2400340RS-C1001片青岛睿森生物科技有限公司1CXHL2400339PH009-1片苏州浦合医药科技有限公司1CXHL2400336PH009-1片苏州浦合医药科技有限公司1CXHL2400335CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400334CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400333CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400332CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400331HRS-7249注射液上海拓界生物医药科技有限公司1CXHL2400329BC-007默化(无锡)生物科技有限公司1CXHL2400326GFH375片劲方医药科技(上海)有限公司1CXHL2400328GFH375片劲方医药科技(上海)有限公司1CXHL2400327注射用WP1302百明信康生物技术(浙江)有限公司1CXHL2400318洛索洛芬钠凝胶贴膏海南赛立克药业有限公司4CYHL2400073注射用BL-M17D1成都百利多特生物药业有限责任公司1CXSL2400237重组抗HER3人源化单抗注射液上海生物制品研究所有限责任公司1CXSL2400232注射用LM-2417礼新医药科技(上海)有限公司1CXSL2400223AK129注射液康方汇科(上海)生物有限公司1CXSL2400220CM355北京天诺健成医药科技有限公司1CXSL2400217IMC-002宜明凯尔生物医药技术(上海)有限公司1CXSL2400219IMC-002宜明凯尔生物医药技术(上海)有限公司1CXSL2400216注射用SKB518四川科伦博泰生物医药股份有限公司1CXSL2400215注射用MK-2870默沙东研发(中国)有限公司1CXSL2400214司美格鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400241司美格鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400240LPS-001注射液乐普药业股份有限公司3.3CXSL2400231QL2108注射液齐鲁制药有限公司3.3CXSL2400221泰它西普注射液荣昌生物制药(烟台)股份有限公司2.1;2.2CXSL2400213 仿制药申请药品名称企业注册分类受理号盐酸异丙肾上腺素注射液成都欣捷高新技术开发股份有限公司3CYHS2301346盐酸异丙肾上腺素注射液成都欣捷高新技术开发股份有限公司3CYHS2301345甲硫酸新斯的明注射液陕西丽彩药业有限公司3CYHS2300705甲硫酸新斯的明注射液陕西丽彩药业有限公司3CYHS2300704美索巴莫注射液南京赛瑞谱顿制药有限公司3CYHS2300368盐酸非索非那定干混悬剂济川药业集团有限公司3CYHS2201943国;CYHS2201943盐酸非索非那定干混悬剂济川药业集团有限公司3CYHS2201942国;CYHS2201942盐酸氨溴索滴剂丽彩甘肃西峰制药有限公司3CYHS2201844国;CYHS2201844盐酸氨溴索滴剂丽彩甘肃西峰制药有限公司3CYHS2201843国;CYHS2201843盐酸左沙丁胺醇雾化吸入溶液宏越科技(湖州)有限公司3CYHS2201800国;CYHS2201800盐酸左沙丁胺醇雾化吸入溶液宏越科技(湖州)有限公司3CYHS2201799国;CYHS2201799己酮可可碱注射液江西和盈药业有限公司3CYHS2201773国;CYHS2201773铝碳酸镁混悬液杭州民生健康药业股份有限公司3CYHS2201508国;CYHS2201508利伐沙班细粒剂浙江恒研医药科技有限公司3CYHS2201485国;CYHS2201485利伐沙班细粒剂浙江恒研医药科技有限公司3CYHS2201484国;CYHS2201484人纤维蛋白原广东双林生物制药有限公司3.4CXSS2300008醋酸阿托西班注射液湖南科伦制药有限公司4CYHS2303412醋酸阿托西班注射液湖南科伦制药有限公司4CYHS2303411氟比洛芬凝胶贴膏河北鼎泰制药有限公司4CYHS2302482氢溴酸伏硫西汀片石家庄龙泽制药股份有限公司4CYHS2302355磷酸奥司他韦胶囊安徽省先锋制药有限公司4CYHS2302241磷酸奥司他韦胶囊安徽省先锋制药有限公司4CYHS2302239注射用甲泼尼龙琥珀酸钠海南倍特药业有限公司4CYHS2302171鲑降钙素注射液海南紫程众投生物科技有限公司4CYHS2302116罗库溴铵注射液陕西金思铭生物技术有限公司4CYHS2302031罗库溴铵注射液陕西金思铭生物技术有限公司4CYHS2302030黄体酮阴道缓释凝胶浙江爱生药业有限公司4CYHS2301662硫酸氨基葡萄糖胶囊山东朗诺制药有限公司4CYHS2300975硫酸氨基葡萄糖胶囊药大制药有限公司4CYHS2300757乳酸环丙沙星氯化钠注射液江苏长江药业有限公司4CYHS2300644盐酸艾司洛尔氯化钠注射液石家庄四药有限公司4CYHS2300581左卡尼汀口服溶液浙江北生药业汉生制药有限公司4CYHS2300528麦考酚钠肠溶片四川科伦药业股份有限公司4CYHS2300453复方电解质注射液广东科伦药业有限公司4CYHS2300379复方电解质注射液广东科伦药业有限公司4CYHS2300378尼莫地平注射液四川汇宇制药股份有限公司4CYHS2300281布南色林片合肥英太制药有限公司4CYHS2300237富马酸喹硫平缓释片山东京卫制药有限公司4CYHS2300181左西孟旦注射液海南倍特药业有限公司4CYHS2300170精氨酸布洛芬颗粒海南葫芦娃药业集团股份有限公司4CYHS2300159氯苯唑酸葡胺软胶囊齐鲁制药有限公司4CYHS2300076尼莫地平注射液北京柏雅联合药物研究所有限公司4CYHS2300056利托那韦片海南先声药业有限公司4CYHS2300046骨化三醇注射液成都国为生物医药有限公司4CYHS2201941国;CYHS2201941他达拉非片河南比福制药股份有限公司4CYHS2201830国;CYHS2201830磷酸奥司他韦胶囊山东新时代药业有限公司4CYHS2201767国;CYHS2201767磷酸奥司他韦胶囊山东新时代药业有限公司4CYHS2201766国;CYHS2201766磷酸奥司他韦胶囊山东新时代药业有限公司4CYHS2201765国;CYHS2201765罗库溴铵注射液江苏正大清江制药有限公司4CYHS2201743国;CYHS2201743甲泼尼龙片辰欣药业股份有限公司4CYHS2201704国;CYHS2201704贝前列素钠片重庆药友制药有限责任公司4CYHS2201706国;CYHS2201706孟鲁司特钠咀嚼片海南葫芦娃药业集团股份有限公司4CYHS2201672国;CYHS2201672孟鲁司特钠咀嚼片海南葫芦娃药业集团股份有限公司4CYHS2201671国;CYHS2201671注射用氯诺昔康广州曼翔医药有限公司4CYHS2201418国;CYHS2201418普瑞巴林胶囊江苏恩华药业股份有限公司4CYHS2201265国;CYHS2201265结构脂肪乳注射液(C6-24)四川国瑞药业有限责任公司4CYHS2201238国;CYHS2201238富马酸丙酚替诺福韦片温岭市创新生物医药科技股份有限公司4CYHS2200916国;CYHS2200916醋酸奥曲肽注射液四川汇宇制药股份有限公司4CYHS2200889国;CYHS2200889普瑞巴林胶囊山东新华制药股份有限公司4CYHS2200880国;CYHS2200880普瑞巴林胶囊山东新华制药股份有限公司4CYHS2200879国;CYHS2200879富马酸伏诺拉生片宜昌人福药业有限责任公司4CYHS2200735国;CYHS2200735富马酸伏诺拉生片宜昌人福药业有限责任公司4CYHS2200734国;CYHS2200734磷酸西格列汀片苏州天马医药集团天吉生物制药有限公司4CYHS2200560国;CYHS2200560磷酸西格列汀片苏州天马医药集团天吉生物制药有限公司4CYHS2200559国;CYHS2200559磷酸西格列汀片苏州天马医药集团天吉生物制药有限公司4CYHS2200558国;CYHS2200558左乙拉西坦口服溶液湖南嘉恒制药有限公司4CYHS2200388国;CYHS2200388 进口申请药品名称企业注册分类受理号磷酸芦可替尼片Novartis Pharma Schweiz AG5.1JXHS2300054盐酸卡马替尼片Novartis Pharma Schweiz AG5.1JXHS2300024盐酸卡马替尼片Novartis Pharma Schweiz AG5.1JXHS2300023亚甲蓝肠溶缓释片Alfasigma S.p.A.5.1JXHS2300021爱塔乐伦颗粒口服干混悬剂PTC Therapeutics International Limited5.1JXHS2200031国;JXHS2200031爱塔乐伦颗粒口服干混悬剂PTC Therapeutics International Limited5.1JXHS2200030国;JXHS2200030爱塔乐伦颗粒口服干混悬剂PTC Therapeutics International Limited5.1JXHS2200029国;JXHS2200029地拉罗司颗粒MSN Laboratories Private Limited5.2JYHS2200036国;JYHS2200036地拉罗司颗粒MSN Laboratories Private Limited5.2JYHS2200035国;JYHS2200035注射用多黏菌素E甲磺酸钠Xellia Pharmaceuticals ApS5.2JYHS2101061国;JYHS2101061利奈唑胺葡萄糖注射液北京费森尤斯卡比医药有限公司5.2JYHS2000050国;JYHS2000050BAY 2862789口服溶液Bayer AG1JXHL2400081Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400080Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400079Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400078Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400077Capivasertib片AstraZeneca AB2.4JXHL2400087Capivasertib片AstraZeneca AB2.4JXHL2400086VAY736注射液Novartis Pharma AG1JXSL2400070BAY 3018250Bayer AG1JXSL2400068帕博利珠单抗注射液Merck Sharp & Dohme LLC2.2JXSL2400074Ravulizumab注射液Alexion Pharmaceuticals Inc.3.1JXSL2400075 中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

申请上市

2024-06-14

·药融圈

8亿+高端吸入制剂，健康元药业拿下首仿！

▲8月15-16日 NDC2024生物医药创新者峰会扫码立即报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。 6月12日，据NMPA官网公示，健康元药业集团的沙美特罗替卡松吸入粉雾剂获批上市并视同过评，为国内首仿。据药融云数据库显示，沙美特罗替卡松吸入粉雾剂在2022年全国院内市场销售额超8亿元。截图来源：NMPA官网沙美特罗替卡松吸入粉雾剂原研来自葛兰素史克（GSK）公司的舒利迭，是沙美特罗与丙酸氟替卡松的复方吸入粉雾剂，用于可逆性阻塞性气道疾病的规律治疗，包括哮喘及慢性阻塞性肺疾病。据药融云数据库显示，沙美特罗替卡松吸入粉雾剂在2022年全国院内市场销售额超8亿元，是吸入剂TOP5产品。截图来源：药融云全国医院销售数据库此前，沙美特罗替卡松吸入粉雾剂仅有葛兰素史克拥有生产批文，国内暂无仿制药获批。此次健康元顺利获批上市，为国内首仿。截图来源：药融云中国药品批文数据库目前，沙美特罗替卡松吸入粉雾剂还有深圳市泛谷药业、上海欧米尼医药、杭州京瑞医药科技、四川普锐特药业、苏州欧米尼医药等药企提交了申请上市，均在审评审批中。截图来源：药融云中国药品审评数据库截至目前，健康元已有吸入用布地奈德混悬液、异丙托溴铵雾化吸入溶液、吸入用乙酰半胱氨酸溶液等8款吸入制剂过评，其中异丙托溴铵雾化吸入溶液、吸入用复方异丙托溴铵溶液、沙美特罗替卡松吸入粉雾剂、盐酸左沙丁胺醇雾化吸入溶液4个品种为首家过评。 END 版权声明：本文转自药融云，如不希望被转载的媒体或个人可与我们联系，我们将立即删除【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

上市批准

2024-05-31

·米内网

【关注】大涨100%吸入剂，上海药企拿下首仿

精彩内容日前，健康元药业公告称，其控股子公司上海方予健康医药申报的4类仿制药丙酸氟替卡松雾化吸入用混悬液获批生产并视同过评，为国内首仿（不含原研及原研地产化）。米内网数据显示，2023年中国公立医疗机构终端丙酸氟替卡松雾化吸入用混悬液销售额超过3亿元，同比增长约100%。丙酸氟替卡松是一种具有抗炎活性的合成三氟化糖皮质激素，具有亲脂性高、受体亲和力强等药理优势。丙酸氟替卡松雾化吸入用混悬液为吸入糖皮质激素(ICS)类药物，通过局部抗炎作用，发挥哮喘治疗效果，适用于4-16岁儿童及青少年轻度至中度哮喘急性发作的治疗。GSK的丙酸氟替卡松雾化吸入用混悬液于2017年获得CDE批准进入中国市场，目前已被纳入全国医保乙类目录。米内网数据显示，近年来该产品在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端的销售额逐年上涨，2023年超过3亿元，同比增长约100%。近年来中国公立医疗机构终端丙酸氟替卡松雾化吸入用混悬液销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局上海方予健康医药的丙酸氟替卡松雾化吸入用混悬液于2022年2月提交上市申请并获受理，并于日前顺利获批上市，为国内首仿（不含原研及原研地产化）。另有1家企业（按上市许可申请人计）以仿制4类报产在审，为上海新黄河制药。吸入剂是健康元药业重点布局的领域之一，目前公司已有9款吸入剂获批上市。米内网数据显示，近年来中国公立医疗机构终端吸入剂销售额均超过200亿元。健康元药业已获批上市的吸入剂来源：米内网中国上市药品（MID）数据库9款吸入剂中，妥布霉素吸入溶液为2类新药，丙酸氟替卡松雾化吸入用混悬液、盐酸左沙丁胺醇雾化吸入溶液、吸入用复方异丙托溴铵溶液等为国内首仿。资料来源：米内网数据库、公司公告等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至5月31日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准

100 项与盐酸左沙丁胺醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸左沙丁胺醇	R03CC	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
气道阻塞	中国	健康元药业集团股份有限公司	2019-09-26
支气管痉挛	美国	Hikma Pharmaceuticals USA, Inc.	1999-03-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床3期	美国	Sumitomo Pharma America, Inc.	2000-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02802111 (CTgov)	N/A	-	24	Albuterol (Albuterol 5 mg First, Then Levalbuterol 2.5 mg)	範夢鏇願鹹獵選膚壓醖(鬱淵憲鬱範衊廠網獵積) = 鬱糧範獵鑰淵醖鏇艱鏇鑰簾獵鏇餘鹽範構窪膚 (遞積構遞壓窪壓膚齋製, 齋鬱襯壓膚鏇夢觸顧廠 ~ 範鬱網製膚簾廠壓廠襯) 更多	-	2020-10-28
				Levalbuterol (Levalbuterol 2.5 mg First, Then Albuterol 5 mg)	範夢鏇願鹹獵選膚壓醖(鬱淵憲鬱範衊廠網獵積) = 簾簾築築鹽遞願願簾網鑰簾獵鏇餘鹽範構窪膚 (遞積構遞壓窪壓膚齋製, 選鏇襯窪遞憲繭夢糧觸 ~ 膚襯簾窪齋糧積製鹹鹽) 更多
NCT01151579 (CTgov)	临床4期	慢性阻塞性肺疾病 \| 心律失常 \| 脓毒症 ... 更多	89	Levalbuterol+Albuterol	襯蓋齋醖製夢餘構壓夢(網廠糧醖壓鏇繭憲膚夢) = 選製網壓鹹獵構鑰築選膚糧膚壓衊範獵範選獵 (齋網鏇觸網選繭廠繭醖, 齋襯鑰繭淵餘窪觸網淵 ~ 繭醖繭築顧範鏇築鹽襯) 更多	-	2015-10-23
NCT00585039 (CTgov)	临床4期	急性哮喘	101	Levalbuterol (Xopenex) (Levalbuterol (Xopenex))	艱構餘壓遞鹹齋壓夢願(獵膚鏇齋獵鏇餘築鑰鹹) = 構獵蓋製鏇糧範糧艱遞鹽憲膚餘鹽觸獵糧觸顧 (醖遞顧繭遞淵簾網膚鏇, 淵顧壓艱鬱鏇齋鏇鹹製 ~ 網醖範膚襯憲積鹹鏇選) 更多	-	2011-08-16
				Albuterol (Albuterol)	艱構餘壓遞鹹齋壓夢願(獵膚鏇齋獵鏇餘築鑰鹹) = 夢壓艱觸構醖鹽簾積夢鹽憲膚餘鹽觸獵糧觸顧 (醖遞顧繭遞淵簾網膚鏇, 顧繭艱顧繭獵壓築構鑰 ~ 遞築艱鬱簾構鏇艱築鹽) 更多